Health
Pfizer/BioNTech COVID-19 vaccine continues to show strong effect in early-stage study – Seeking Alpha
Data from an ongoing Phase 1/2 clinical trial evaluating three dose levels of Pfizer (NYSE:PFE) and collaboration partner BioNTech SE’s (NASDAQ:BNTX) COVID-19 vaccine candidate BNT162b1 in healthy volunteers showed an acceptable safety profile and dose-depend…
Data from an ongoing Phase 1/2 clinical trial evaluating three dose levels of Pfizer (NYSE:PFE) and collaboration partner BioNTech SE’s (NASDAQ:BNTX) COVID-19 vaccine candidate BNT162b1 in healthy volunteers showed an acceptable safety profile and dose-dependent increases in glycoprotein receptor-binding domain (RBD)-binding IgG concentrations and SARS-CoV-2 neutralizing antibody titers. The data, just published in the journal Nature, was generated on the first two dose levels, 10 µg and 30 µg. …
-
Noosa News23 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
Noosa News22 hours agoDefence investigation finds Taipan pilot’s actions possibly prevented further fatalities in crash
-
Noosa News21 hours agoNo matter what happens in his Origin debut, history beckons for rookie maroon Robert Toia
-
General19 hours agoDairy farmers devastated by floods across parts of New South Wales